Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5584 | 2021 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2886 | 2020 |
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1754 | 2020 |
Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant SA Madhi, V Baillie, CL Cutland, M Voysey, AL Koen, L Fairlie, ... New England Journal of Medicine 384 (20), 1885-1898, 2021 | 1416 | 2021 |
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1394 | 2021 |
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment OJ Wouters, KC Shadlen, M Salcher-Konrad, AJ Pollard, HJ Larson, ... The Lancet 397 (10278), 1023-1034, 2021 | 1390 | 2021 |
A guide to vaccinology: from basic principles to new developments AJ Pollard, EM Bijker Nature Reviews Immunology 21 (2), 83-100, 2021 | 1347 | 2021 |
Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1178 | 2021 |
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection S Feng, DJ Phillips, T White, H Sayal, PK Aley, S Bibi, C Dold, M Fuskova, ... Nature medicine 27 (11), 2032-2040, 2021 | 1134 | 2021 |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 985 | 2022 |
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a … Y Li, X Wang, DM Blau, MT Caballero, DR Feikin, CJ Gill, SA Madhi, ... The Lancet 399 (10340), 2047-2064, 2022 | 928 | 2022 |
COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II D Freeman, BS Loe, A Chadwick, C Vaccari, F Waite, L Rosebrock, ... Psychological medicine 52 (14), 3127-3141, 2022 | 843 | 2022 |
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 SH Hodgson, K Mansatta, G Mallett, V Harris, KRW Emary, AJ Pollard The lancet infectious diseases 21 (2), e26-e35, 2021 | 798 | 2021 |
Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum C Liu, HM Ginn, W Dejnirattisai, P Supasa, B Wang, A Tuekprakhon, ... Cell 184 (16), 4220-4236. e13, 2021 | 775 | 2021 |
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 761 | 2021 |
Antibody evasion by the P. 1 strain of SARS-CoV-2 W Dejnirattisai, D Zhou, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (11), 2939-2954. e9, 2021 | 671 | 2021 |
Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum A Tuekprakhon, R Nutalai, A Dijokaite-Guraliuc, D Zhou, HM Ginn, ... Cell 185 (14), 2422-2433. e13, 2022 | 659 | 2022 |
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 635 | 2021 |
Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines AJ Pollard, KP Perrett, PC Beverley Nature Reviews Immunology 9 (3), 213-220, 2009 | 588 | 2009 |
Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (8), 2201-2211. e7, 2021 | 506 | 2021 |